Dr Reddy’s Laboratories launches Testosterone Gel in the US

Hyderabad-headquartered Dr Reddy’s Laboratories said it has launched a therapeutic equivalent of AbbVie Inc’s AndroGel in the US market, a month after rival Lupin did so.

Testosterone Gel is used for hormone replacement in men who are not able to produce enough testosterone. The medication is absorbed through the skin, enters the bloodstream, and helps the body reach normal testosterone levels.

As of February 2019, Testosterone Gel 1.62% had annual sales of $816 million in the US market.

Mumbai-based rival Lupin had launched a generic equivalent of AndroGel in the US market last month.

Established in 1984, Dr Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.